G. Bergseth

发表

Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person.

John D Lambris, Tom Eirik Mollnes, Knut Tore Lappegård, 2011, The Annals of thoracic surgery.

Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.

T. Mollnes, M. Fung, K. Lappegård, 2004, The Annals of thoracic surgery.

Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.

John D Lambris, J. Lambris, V. Videm, 2004, The Annals of thoracic surgery.

Role of granulocytes and monocytes in the polyvinyl chloride-induced synthesis of interleukin 8, monocyte chemoattractant protein 1, and leukotriene B4.

Joseph Sexton, T. Mollnes, K. Lappegård, 2005, Journal of biomedical materials research. Part A.

Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production.

John D Lambris, J. Lambris, T. Mollnes, 2005, The Annals of thoracic surgery.

A Conformational Change of Complement C5 Is Required for Thrombin-Mediated Cleavage, Revealed by a Novel Ex Vivo Human Whole Blood Model Preserving Full Thrombin Activity

P. Nilsson, M. Huber-Lang, T. Mollnes, 2021, The Journal of Immunology.

Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome

V. Bosnes, A. Barratt-Due, T. Mollnes, 2017, Medicine.

Human genetic deficiencies reveal the roles of complement in the inflammatory network: Lessons from nature

John D Lambris, B. C. Hellerud, J. Lambris, 2009, Proceedings of the National Academy of Sciences.

Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.

John D Lambris, J. Lambris, J. Köhl, 2002, Blood.

An international serum standard for application in assays to detect human complement activation products.

Bo Nilsson, B. Nilsson, T. Mollnes, 2013, Molecular immunology.

Eculizumab‐C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses

P. Nilsson, E. Volokhina, L. P. Van den Heuvel, 2017, Molecular immunology.

Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.

J. Andersen, I. Sandlie, Stian Foss, 2015, Immunobiology.

Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.

John D Lambris, B. C. Hellerud, J. Lambris, 2011, Molecular immunology.

NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies

J. Andersen, T. Espevik, J. Bruun, 2019, mAbs.

Platelet Compatibility of an Artificial Surface Modified with Functionally Active Heparin

V. Videm, T. Hovig, T. Mollnes, 1999, Thrombosis and Haemostasis.

Granulocyte and monocyte CD11b expression during plasma separation is dependent on complement factor 5 (C5) – an ex vivo study with blood from a C5‐deficient individual

T. Mollnes, D. Christiansen, A. Hovland, 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.

J. Wetzels, E. Volokhina, L. P. Van den Heuvel, 2015, Clinical immunology.

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

E. Volokhina, L. P. Van den Heuvel, T. Mollnes, 2015, Blood.

Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis

B. C. Hellerud, P. Brandtzæg, T. Espevik, 2017, Journal of Intensive Care.

Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

G. Tjønnfjord, P. Holme, H. Orrem, 2016, Rheumatology.

Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli‐induced coagulation accompanied by Toll‐like receptor 4

T. Woodruff, T. Espevik, T. Mollnes, 2018, Clinical and experimental immunology.

Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome

V. Bosnes, T. Mollnes, D. Karpman, 2018, Case reports in nephrology.

Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.

P. Garred, T. Mollnes, G. Bergseth, 1988, Clinical and experimental immunology.

A novel enzyme immunoassay for plasma thrombospondin. Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo.

V. Videm, T. Mollnes, K. Lappegård, 2000, Thrombosis research.

Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.

J. Andersen, I. Sandlie, Stian Foss, 2015, Immunobiology.

The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent.

John D Lambris, J. Lambris, T. Mollnes, 2008, Journal of biomedical materials research. Part A.

Electroluminescent TCC, C3dg and fB/Bb epitope assays for profiling complement cascade activation in vitro using an activated complement serum calibration standard.

A. M. Shaw, T. Mollnes, T E Mollnes, 2014, Journal of immunological methods.